FDA wants another study on Adventrx' reformulated cancer drug
This article was originally published in Scrip
Executive Summary
The US FDA has refused to approve Adventrx Pharmaceuticals' cancer product candidate ANX-514 (docetaxel emulsion, a reformulation of Sanofi-Aventis' Taxotere), based on findings from a bioequivalence study, said the firm.